Tag: Tigecycline

Nontuberculous mycobacterial (NTM) infections are becoming increasingly prevalent worldwide [1.2.2]. A key question for clinicians and patients is: **What antibiotics treat *Mycobacterium abscessus*?** This bacterium is known for its extensive drug resistance, making treatment particularly challenging [1.7.5].

In the United States, more than 2.8 million antimicrobial-resistant infections occur each year, leading to over 35,000 deaths [1.4.2, 1.4.4]. This growing crisis necessitates the use of powerful medications, but **what is a last resort antibiotic?**

Tigecycline, a first-in-class glycylcycline antibiotic, was developed to combat the rising threat of multidrug-resistant (MDR) pathogens. Approved in 2005, it is a crucial intravenous treatment reserved for serious infections when other antibiotics are ineffective or unsuitable.